|
US5120722A
(en)
|
1984-02-08 |
1992-06-09 |
Hoffmann-La Roche Inc. |
Trihydroxy-cholecacliferol and trihydroxy-ergocalciferol for treating leukemia
|
|
US4857518A
(en)
|
1984-10-04 |
1989-08-15 |
Wisconsin Alumni Research Foundation |
Hydroxylated 24-homo-vitamin D derivatives and methods for preparing same
|
|
US4717721A
(en)
|
1985-05-30 |
1988-01-05 |
Howard W. Bremer |
Sidechain homo-vitamin D compounds with preferential anti-cancer activity
|
|
WO1987000834A1
(en)
|
1985-08-02 |
1987-02-12 |
Leo Pharmaceutical Products Ltd. A/S |
Novel vitamin d analogues
|
|
US5145846A
(en)
|
1988-01-20 |
1992-09-08 |
Hoffmann-La Roche Inc. |
Vitamin D3 analogs
|
|
US4851401A
(en)
|
1988-07-14 |
1989-07-25 |
Wisconsin Alumni Research Foundation |
Novel cyclopentano-vitamin D analogs
|
|
CA1333616C
(en)
|
1989-03-09 |
1994-12-20 |
Hector F. Deluca |
19-nor-vitamin d compounds
|
|
GB8915770D0
(en)
|
1989-07-10 |
1989-08-31 |
Leo Pharm Prod Ltd |
Chemical compounds
|
|
US4966898A
(en)
|
1989-08-15 |
1990-10-30 |
Merrell Dow Pharmaceuticals Inc. |
4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
|
|
DE4021433A1
(de)
|
1990-07-04 |
1992-01-09 |
Schering Ag |
Antiandrogene mit steroid(3,2-c)pyrazol-struktur
|
|
DE4101953A1
(de)
|
1991-01-19 |
1992-07-23 |
Schering Ag |
23-oxa-derivate in der vitamin-d-reihe, verfahren zu ihrer herstellung diese derivate enthaltende pharmazeutische praeparate sowie deren verwendung als arzneimittel
|
|
DE4141746A1
(de)
|
1991-12-13 |
1993-06-17 |
Schering Ag |
20-methyl-substituierte vitamin d-derivate
|
|
US5604213A
(en)
|
1992-03-31 |
1997-02-18 |
British Technology Group Limited |
17-substituted steroids useful in cancer treatment
|
|
DE69327096T2
(de)
|
1992-03-31 |
2000-06-21 |
Btg International Ltd., London |
17-substituierte steroide, verwendbar bei behandlung von krebs
|
|
US5547947A
(en)
|
1993-03-11 |
1996-08-20 |
Hoffmann-La Roche Inc. |
Methods of treatment
|
|
DE69416419T2
(de)
|
1993-09-30 |
1999-06-10 |
Btg International Ltd., London |
Synthese von 17-(3-pyridyl) steroiden
|
|
US5688977A
(en)
|
1996-02-29 |
1997-11-18 |
Napro Biotherapeutics, Inc. |
Method for docetaxel synthesis
|
|
US5919815A
(en)
|
1996-05-22 |
1999-07-06 |
Neuromedica, Inc. |
Taxane compounds and compositions
|
|
CA2255615C
(en)
|
1996-05-22 |
2006-08-29 |
Neuromedica, Inc. |
Compositions comprising conjugates of cis-docosahexaenoic acid and docetaxel
|
|
US5795909A
(en)
|
1996-05-22 |
1998-08-18 |
Neuromedica, Inc. |
DHA-pharmaceutical agent conjugates of taxanes
|
|
GB9622590D0
(en)
|
1996-10-30 |
1997-01-08 |
Leo Pharm Prod Ltd |
Chemical compounds
|
|
US20020128240A1
(en)
|
1996-12-30 |
2002-09-12 |
Bone Care International, Inc. |
Treatment of hyperproliferative diseases using active vitamin D analogues
|
|
US6872568B1
(en)
|
1997-03-17 |
2005-03-29 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5 antibodies
|
|
US20050233958A1
(en)
|
1997-03-17 |
2005-10-20 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5
|
|
US6087350A
(en)
|
1997-08-29 |
2000-07-11 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
|
|
EP2340840B1
(en)
|
1998-03-27 |
2012-08-29 |
Oregon Health Sciences University |
Pulse dose Vitamin D drug for the treatment of hyperproliferative skin diseases
|
|
US20030083231A1
(en)
|
1998-11-24 |
2003-05-01 |
Ahlem Clarence N. |
Blood cell deficiency treatment method
|
|
JP2002533404A
(ja)
|
1998-12-23 |
2002-10-08 |
ジー・ディー・サール・アンド・カンパニー |
新生物形成の治療における組合わせ療法としてインテグリン拮抗剤及び放射線治療を使用する方法
|
|
ES2300323T3
(es)
|
2000-03-02 |
2008-06-16 |
Univ Pittsburgh |
Quimioterapia combinada.
|
|
JPWO2001081364A1
(ja)
|
2000-04-24 |
2004-01-08 |
協和醗酵工業株式会社 |
エストラ−１，３，５（１０）−トリエン誘導体
|
|
DE60118571T2
(de)
|
2000-05-15 |
2007-02-01 |
Celgene Corp. |
Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten
|
|
EP1676577A1
(en)
|
2000-05-15 |
2006-07-05 |
Celgene Corporation |
Compositions for the treatment of cancer comprising a topoisomerase inhibitor and thalidomide
|
|
CN1254234C
(zh)
|
2000-06-09 |
2006-05-03 |
莱古伦公司 |
质粒dna(lipogenestm)和含细胞核定位信号/促融合肽缀合物的治疗剂包封到定向脂质体复合体中
|
|
WO2002003286A1
(en)
|
2000-07-05 |
2002-01-10 |
Bryan Muehlberger |
Systems and methods of facilitating electronic payment transactions
|
|
US6656942B2
(en)
|
2000-10-17 |
2003-12-02 |
Merck & Co., Inc. |
Orally active salts with tyrosine kinase activity
|
|
US6750213B2
(en)
|
2000-10-19 |
2004-06-15 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
|
DE10061137B4
(de)
|
2000-12-07 |
2016-10-06 |
Takeda Gmbh |
Neue pharmazeutische Zubereitung
|
|
EP1351678A2
(en)
|
2001-01-02 |
2003-10-15 |
Elizabeth Shanahan-Prendergast |
Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
|
|
JP4489354B2
(ja)
|
2001-04-18 |
2010-06-23 |
ユーロ−セルティーク エス．エイ． |
スピロインデンおよびスピロインダン化合物類
|
|
ES2323876T3
(es)
|
2001-04-18 |
2009-07-27 |
Euro-Celtique S.A. |
Derivados de 1-(4-piperidinil)-1,3-dihidro-2h-benzoxazol-2-ona y compuestos relacionados como analogos de la nociceptina y ligandos de orl1 para el tratamiento del dolor.
|
|
EP1975164B1
(en)
|
2001-04-18 |
2010-01-27 |
Euro-Celtique S.A. |
Octahydrobenzimidazolone compounds as analgetics
|
|
UA74439C2
(uk)
|
2001-04-18 |
2005-12-15 |
Еро-Селтік, С.А. |
Сполуки спіропіразолу
|
|
WO2002091993A2
(en)
|
2001-05-10 |
2002-11-21 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
|
US20040171630A1
(en)
|
2001-06-19 |
2004-09-02 |
Yuntae Kim |
Tyrosine kinase inhibitors
|
|
US6740641B2
(en)
|
2001-07-27 |
2004-05-25 |
Euro-Celtique, S.A. |
Sugar derivatives of hydromorphone, dihydromorphine and dihydromorphine, compositions thereof and uses for treating or preventing pain
|
|
WO2003020699A2
(en)
|
2001-08-30 |
2003-03-13 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
AU2002326823B2
(en)
|
2001-09-06 |
2005-12-15 |
Merck Sharp & Dohme Corp. |
17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
|
|
WO2003037252A2
(en)
|
2001-10-30 |
2003-05-08 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
US7060705B2
(en)
|
2001-11-07 |
2006-06-13 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
|
US7378411B2
(en)
|
2001-12-06 |
2008-05-27 |
Merck & Co., Inc. |
Substituted thienopyrimidinones as a mitotic kinesin inhibitor
|
|
DK1472225T3
(da)
|
2002-02-01 |
2010-08-09 |
Euro Celtique Sa |
2-Piperazinpyridiner, som er anvendelige til behandling af smerte
|
|
EP1336602A1
(en)
|
2002-02-13 |
2003-08-20 |
Giovanni Scaramuzzino |
Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
|
|
US6974818B2
(en)
|
2002-03-01 |
2005-12-13 |
Euro-Celtique S.A. |
1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
|
|
US20050159361A1
(en)
|
2002-03-11 |
2005-07-21 |
Takahito Hara |
Remedies for sex hormone-dependent disease
|
|
US7273869B2
(en)
|
2002-04-08 |
2007-09-25 |
Merck & Co., Inc. |
Inhibitors of Akt activity
|
|
EP1927858B1
(en)
|
2002-04-29 |
2013-01-09 |
Euro-Celtique S.A. |
Conformationally constrained peptides that bind the ORL-1 receptor
|
|
EP1503757B1
(en)
|
2002-05-02 |
2007-12-19 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
JP4463679B2
(ja)
|
2002-06-14 |
2010-05-19 |
メルク エンド カムパニー インコーポレーテッド |
有糸分裂キネシン阻害剤
|
|
WO2004002983A2
(en)
|
2002-06-28 |
2004-01-08 |
Euro-Celtique, S.A. |
Therapeutic piperazine derivatives useful for treating pain
|
|
US8268352B2
(en)
|
2002-08-05 |
2012-09-18 |
Torrent Pharmaceuticals Limited |
Modified release composition for highly soluble drugs
|
|
US7985422B2
(en)
|
2002-08-05 |
2011-07-26 |
Torrent Pharmaceuticals Limited |
Dosage form
|
|
US8216609B2
(en)
|
2002-08-05 |
2012-07-10 |
Torrent Pharmaceuticals Limited |
Modified release composition of highly soluble drugs
|
|
AU2003259835A1
(en)
|
2002-08-15 |
2004-03-03 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to trail receptors
|
|
US20040138187A1
(en)
|
2002-08-28 |
2004-07-15 |
Reading Christopher L. |
Therapeutic treatment methods
|
|
US20050101581A1
(en)
|
2002-08-28 |
2005-05-12 |
Reading Christopher L. |
Therapeutic treatment methods 2
|
|
US7157462B2
(en)
|
2002-09-24 |
2007-01-02 |
Euro-Celtique S.A. |
Therapeutic agents useful for treating pain
|
|
CN100528167C
(zh)
|
2002-10-23 |
2009-08-19 |
潘塔希生物科学股份有限公司 |
用于治疗癌症的包含雌四醇衍生物的药物组合物
|
|
EP1558609A4
(en)
|
2002-10-30 |
2008-05-28 |
Merck & Co Inc |
KINASE INHIBITORS
|
|
US7202259B2
(en)
|
2002-11-18 |
2007-04-10 |
Euro-Celtique S.A. |
Therapeutic agents useful for treating pain
|
|
CN1744930A
(zh)
|
2002-12-17 |
2006-03-08 |
先灵公司 |
治疗雄激素依赖性疾病的3型17β－羟基类固醇脱氢酶抑制剂
|
|
US7582635B2
(en)
|
2002-12-24 |
2009-09-01 |
Purdue Pharma, L.P. |
Therapeutic agents useful for treating pain
|
|
WO2004062620A2
(en)
|
2003-01-13 |
2004-07-29 |
Cedars-Sinai Medical Center |
Paricalcitol as a chemotherapeutic agent
|
|
TWI330079B
(en)
|
2003-01-15 |
2010-09-11 |
Synta Pharmaceuticals Corp |
Treatment for cancers
|
|
CA2524737A1
(en)
|
2003-05-06 |
2005-02-24 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to trail receptors
|
|
US20050020546A1
(en)
|
2003-06-11 |
2005-01-27 |
Novacea, Inc. |
Pharmaceutical compositions comprising active vitamin D compounds
|
|
TWI287010B
(en)
|
2003-06-12 |
2007-09-21 |
Euro Celtique Sa |
Therapeutic agents useful for treating pain
|
|
EP1867644B1
(en)
|
2003-07-24 |
2009-05-20 |
Euro-Celtique S.A. |
Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
|
|
DE602004021206D1
(de)
|
2003-07-24 |
2009-07-02 |
Euro Celtique Sa |
Zur Behandlung oder Vorbeugung von Schmerzen geeignete Heteroaryl-Tetrahydropiperidyl-Verbindungen
|
|
US7071333B2
(en)
|
2003-07-30 |
2006-07-04 |
Bristol-Myers Squibb Company |
Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
|
|
PT1648880E
(pt)
|
2003-08-01 |
2010-04-26 |
Euro Celtique Sa |
Agentes terapêuticos úteis para o tratamento da dor
|
|
AU2004268707A1
(en)
|
2003-08-27 |
2005-03-10 |
Merck Frosst Canada Ltd |
Cathepsin inhibitors
|
|
PL1664041T3
(pl)
|
2003-09-22 |
2008-12-31 |
Euro Celtique Sa |
Przydatne do leczenia bólu związki fenylowo-karboksyamidowe
|
|
ES2317052T3
(es)
|
2003-09-22 |
2009-04-16 |
Euro-Celtique S.A. |
Agentes terapeuticos utiles para el tratamiento del dolor.
|
|
AU2004283479A1
(en)
|
2003-10-17 |
2005-05-06 |
4 Aza Bioscience Nv |
Heterocycle-substituted pteridine derivatives and their use in therapy
|
|
US7445794B1
(en)
|
2004-04-29 |
2008-11-04 |
The Regents Of The University Of Colorado |
Methods for treating human proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors
|
|
US20060003950A1
(en)
|
2004-06-30 |
2006-01-05 |
Bone Care International, Inc. |
Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
|
|
US7094775B2
(en)
|
2004-06-30 |
2006-08-22 |
Bone Care International, Llc |
Method of treating breast cancer using a combination of vitamin D analogues and other agents
|
|
US20060030608A1
(en)
|
2004-08-04 |
2006-02-09 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Anti aromatase compounds pharmaceutical compositions and uses thereof
|
|
GB0418900D0
(en)
|
2004-08-24 |
2004-09-29 |
Btg Int Ltd |
Novel salt forms
|
|
AU2005281797B2
(en)
|
2004-09-10 |
2011-07-07 |
Jagotec Ag |
Tablets with site and time-controlled gastrointestinal release of active ingredient
|
|
AR051597A1
(es)
|
2004-11-01 |
2007-01-24 |
Merck & Co Inc |
Moduladores de los receptores de estrogeno
|
|
EP1674479A1
(en)
|
2004-12-22 |
2006-06-28 |
Memorial Sloan-Kettering Cancer Center |
Modulation of Fc Gamma receptors for optimizing immunotherapy
|
|
WO2006081152A2
(en)
|
2005-01-24 |
2006-08-03 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
|
KR20080018874A
(ko)
|
2005-04-27 |
2008-02-28 |
유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. |
인간 질병과 관련된 돌연변이 단백질의 분해 촉진을 위한물질 및 방법
|
|
AU2006239896A1
(en)
|
2005-04-28 |
2006-11-02 |
The Regents Of The University Of Colorado |
Therapeutic bifunctional compounds
|
|
US7709517B2
(en)
|
2005-05-13 |
2010-05-04 |
The Regents Of The University Of California |
Diarylhydantoin compounds
|
|
EP1909812A4
(en)
|
2005-07-27 |
2009-11-25 |
Univ Florida |
SMALL CONNECTIONS FOR THE CORRECTION OF PROTEIN MISFAIRINGS AND USES THEREOF
|
|
JP4611441B2
(ja)
|
2006-04-03 |
2011-01-12 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー |
ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール及びベンゾトリアゾール誘導体
|
|
AU2007300734A1
(en)
|
2006-06-02 |
2008-04-03 |
Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
RNA nanoparticles and nanotubes
|
|
WO2008005268A1
(en)
|
2006-06-30 |
2008-01-10 |
Schering Corporation |
Substituted piperidines that increase p53 activity and the uses thereof
|
|
MX2009000132A
(es)
|
2006-06-30 |
2009-01-26 |
Schering Corp |
Metodo para el uso de piperidinas sustituidas que incrementan la actividad de p53.
|
|
US20080051375A1
(en)
|
2006-08-25 |
2008-02-28 |
Auerbach Alan H |
Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
|
|
RS62034B1
(sr)
|
2006-08-25 |
2021-07-30 |
Janssen Oncology Inc |
Kompozicije za lečenje raka
|
|
US20080051380A1
(en)
|
2006-08-25 |
2008-02-28 |
Auerbach Alan H |
Methods and compositions for treating cancer
|
|
EP2081964A4
(en)
|
2006-10-12 |
2012-07-11 |
Univ Johns Hopkins |
ALGINATE AND ALGINATLYASE COMPOSITIONS AND USE METHOD
|
|
US20100168228A1
(en)
|
2006-10-13 |
2010-07-01 |
Reliance Life Sciences Pvt. Ltd. |
Novel chemotherapeutic agents against inflammation and cancer
|
|
GEP20115337B
(en)
|
2007-01-10 |
2011-11-25 |
St Di Ricerche Di Biologia Molecolare P Angeletti Spa |
Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
|
|
EP2491923A3
(en)
|
2007-02-15 |
2012-12-26 |
Novartis AG |
Combinations of therapeutic agents for treating cancer
|
|
WO2008109740A2
(en)
|
2007-03-06 |
2008-09-12 |
Colby Pharmaceutical Company |
Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers
|
|
WO2009009132A1
(en)
|
2007-07-12 |
2009-01-15 |
Cougar Biotechnology, Inc. |
Use of 17alpha-hydroxylase/c17, 20-lyase inhibitors for the treatment of cancer
|
|
NZ586675A
(en)
*
|
2008-01-08 |
2012-04-27 |
Merck Sharp & Dohme |
Pharmaceutically acceptable salts of 2-{ 4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
|
|
RU2506267C2
(ru)
|
2008-03-31 |
2014-02-10 |
Дженентек, Инк. |
Бензопирановые и бензоксепиновые ингибиторы рi3k и их применение
|
|
MX2010011924A
(es)
|
2008-05-07 |
2010-11-30 |
Cardioxyl Pharmaceuticals Inc |
Nuevos compuestos nitrosos como donadores de nitroxilo y metodos de uso de los mismos.
|
|
WO2012009475A1
(en)
|
2010-07-14 |
2012-01-19 |
Oregon Health & Science University |
Methods of treating cancer with inhibition of lysine-specific demethylase 1
|
|
WO2012106514A2
(en)
|
2011-02-03 |
2012-08-09 |
Pop Test Cortisol Llc |
System and method for diagnosis and treatment
|
|
US9314473B2
(en)
|
2011-02-03 |
2016-04-19 |
Pop Test Oncology Limited Liability Company |
System and method for diagnosis and treatment
|
|
PT3305285T
(pt)
*
|
2012-09-26 |
2020-11-24 |
Aragon Pharmaceuticals Inc |
Antiandrogénios para o tratamento de cancro da próstata resistente à castração não metastático
|
|
WO2014089324A1
(en)
|
2012-12-07 |
2014-06-12 |
Calitor Sciences, Llc |
Substituted cyclic compounds and methods of use
|
|
WO2014150000A1
(en)
|
2013-03-21 |
2014-09-25 |
Isp Investments Inc. |
Diacetylene film sensitized with photoinitiator and applications of the film
|
|
US9192609B2
(en)
|
2013-04-17 |
2015-11-24 |
Hedgepath Pharmaceuticals, Inc. |
Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
|
|
WO2015023710A1
(en)
*
|
2013-08-12 |
2015-02-19 |
Tokai Pharmaceuticals, Inc. |
Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
|
|
US9987275B2
(en)
|
2014-04-23 |
2018-06-05 |
The Brigham And Women's Hospital, Inc. |
Targeting PARP1 for treatment of TSC and cancers
|
|
US20150344968A1
(en)
|
2014-05-30 |
2015-12-03 |
Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center |
Methods for determining parp inhibitor and platinum resistance in cancer therapy
|
|
US20160160294A1
(en)
|
2014-12-08 |
2016-06-09 |
Tesaro |
Methods and materials for predicting response to niraparib
|
|
US9598459B2
(en)
|
2015-08-03 |
2017-03-21 |
Pop Test Oncology Llc |
Pharmaceutical compositions and methods
|
|
WO2018023017A1
(en)
|
2016-07-29 |
2018-02-01 |
Janssen Pharmaceutica Nv |
Methods of treating prostate cancer
|
|
US11702443B2
(en)
|
2016-10-04 |
2023-07-18 |
Pop Test Oncology Llc |
Therapeutic agents and methods
|
|
US11040037B2
(en)
|
2016-10-04 |
2021-06-22 |
Pop Test Oncology Llc |
Therapeutic agents and methods
|
|
JOP20190244A1
(ar)
|
2017-04-13 |
2019-10-13 |
Janssen Pharmaceutica Nv |
تركيبة علاجية لسرطان البروستاتا
|
|
KR20200068689A
(ko)
|
2017-10-11 |
2020-06-15 |
얀센 온콜로지 인크 |
안드로겐 박탈 요법과 함께 아비라테론 아세테이트 + 프레드니손을 투여하여 전립선암을 치료하는 방법
|